Onxeo Announces its Financial Agenda for 2019

Paris (France), December 20, 2018 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced its financial agenda for 2019.

Event

Date*

Full-year 2018 results

Tuesday, March 12, 2019

Shareholders’ general meeting

Friday, April 26, 2019

Half-year 2019 results

Thursday, July 25, 2019

 

* This preliminary agenda may be modified. Press releases are published after financial markets close.

181220_PR_ONXEO_Agenda-2019